Table 2 Post-translational autophagy events in diseases

Acetylation

TFEB

K91, K103, K116, K430

Activation

Tumor¹¹²

Tumor suppression

TFEB

K274, K279, GCN5-mediated

Inhibition

Neurodegeneration¹¹³

Neurodegeneration exacerbation

P53

K120, Tip60-mediated

Activation

Tumor¹¹⁴

Tumor suppression

P53

K382, SIRT1-mediated

Activation

Tumor¹¹⁵

Tumor suppression

P53

K373, K382, p300/CBP-mediated

Activation

HCC¹¹⁶

Tumor suppression

P53

SIRT1-mediated

Inhibition

sepsis-induced acute kidney injury¹¹⁷

Injury ↑

FOXO1 (cytoplasm)

K262, K265, K274, SIRT2-mediated

Activation

Tumor^15,120

Tumor suppression

FOXO3a

HDAC4-mediaed

Inhibition

Vascular disorder¹²¹

Vascular inflammation ↓

Beclin1

K430, K437, p300- and p300/SIRT1-mediated

Inhibition

Tumor,^124,125 sepsis-induced acute kidney injury^126,127

Tumor development

LC3

SIRT1-mediated

Activation

Liver cancer¹²⁹

Tumor development

ATG5, ATG7

SIRT1-mediated

Activation

Liver cancer¹³⁰

Chemoresistance

STAT3/AKT

SIRT1-mediated

Activation

Adiposity¹³¹

Adipogenesis ↓

STAT1

HDAC4-mediated

Activation

Diabetes¹³²

Podocyte injury

Cortactin/ tubulin

HDAC6-mediated

Inhibition

Juvenile-onset atypical Parkinson’s disease¹³⁴

Protein aggregates accumulation

Microtubules

HDAC6-mediated

Activation

Spinal cord injury¹³⁵

Injury↓

α-tubulin

HDAC6-mediated

Activation

Prostate cancer,¹³⁶ Cockayne syndrome¹³⁷

Tumor suppression, subcutaneous fat ↑

α-tubulin/Tau

HDAC6-mediated

Activation

Neurological disorders¹³⁸

/

Ubiquitination

ULK1

K63-linked, TRAF6-mediated

Activation

CML¹⁴⁰

Tumor development

Beclin1

K63-linked, TRAF6-mediated

Activation

Lung cancer¹⁴⁴

Tumor development

NSCLC¹⁴⁷

Tumor suppression

VPS34

K29, K48-linked

Inhibition

Steatosis¹⁴⁸

Lipid metabolism balance

KLHL20-mediated

Inhibition

diabetes-associated muscle atrophy¹⁴²

–

LC3B

TRAF6-mediated

Activation

Tumor¹⁴⁹

Tumor development

OPTN

K193 sites, K27, K48-linked, HACE1-mediated

Activation

Tumor¹³⁹

Tumor suppression

p62

K420 sites, K11-linked, SPOP-mediated

Inhibition

Prostate cancer^152,153

Tumor development

Phosphorylation

ULK1

S757,S504 p38 MAPK-mediated

Inhibition

Neuroinflammatory diseases¹⁵⁴

Inflammation ↑

ULK1

S469, S495, S533, TOPK-mediated

Inhibition

Glioma¹⁵⁵

Tumor suppression

S405,S415 GSK3β-mediated

Activation

Pancreatic cancer¹⁵⁶

Tumor development

p62

S351, ULK1-mediated

Activation

ALS-FTLD¹⁵⁷

Neurotoxicity

ATG14

S29, ULK1-mediated

Activation

Huntington’s disease¹⁵⁸

Polyglutamine disease protein clearance

ATG5

T101, PAK1-mediated

Inhibition

Brain tumor¹⁶⁰

Tumor development

OPTN

S177, TBK1-meidated

Activation

Infectious disease¹⁶²

Salmonella clearance

OPTN

S526, p85β-mediated

Inhibition

Tumor¹⁶⁵

Tumor development

ATG4B

S383, MST4-mediated

Activation

Glioblastoma¹⁶⁹

Tumor development

FOXO3a

S318, S321, CK1α-mediated

Inhibition

Multiple cancer¹⁷¹

Tumor suppression

FOXO3a

S253, AKT-mediated

Activation

NSCLC¹⁷²

Tumor suppression

Beclin1

PP2A-mediated

Activation

Neurodegeneration, tumor^173,174,175

Disease progress ↓

AMPKα

T172, PP2A-mediated

Activation

ischemia/reperfusion¹⁷⁶

Dysfunctional mitochondria clearance